| Stromal disrupting effects of nab-paclitaxel in pancreatic cancer R Alvarez, M Musteanu, E Garcia-Garcia, PP Lopez-Casas, D Megias, ... British journal of cancer 109 (4), 926-933, 2013 | 304 | 2013 |
| Stat3 is a negative regulator of intestinal tumor progression in ApcMin mice M Musteanu, L Blaas, M Mair, M Schlederer, M Bilban, S Tauber, ... Gastroenterology 138 (3), 1003-1011. e5, 2010 | 187 | 2010 |
| SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis … M Hidalgo, C Plaza, M Musteanu, P Illei, CB Brachmann, C Heise, ... Clinical Cancer Research 21 (21), 4811-4818, 2015 | 141 | 2015 |
| Afatinib restrains K-RAS–driven lung tumorigenesis HP Moll, K Pranz, M Musteanu, B Grabner, N Hruschka, J Mohrherr, ... Science translational medicine 10 (446), eaao2301, 2018 | 123 | 2018 |
| c-RAF ablation induces regression of advanced Kras/Trp53 mutant lung adenocarcinomas by a mechanism independent of MAPK signaling M Sanclemente, S Francoz, L Esteban-Burgos, E Bousquet-Mur, M Djurec, ... Cancer cell 33 (2), 217-228. e4, 2018 | 116 | 2018 |
| Complete regression of advanced pancreatic ductal adenocarcinomas upon combined inhibition of EGFR and C-RAF MT Blasco, C Navas, G Martín-Serrano, O Graña-Castro, CG Lechuga, ... Cancer cell 35 (4), 573-587. e6, 2019 | 98 | 2019 |
| Signal transducer and activator of transcription 3 protects from liver injury and fibrosis in a mouse model of sclerosing cholangitis M Mair, G Zollner, D Schneller, M Musteanu, P Fickert, J Gumhold, ... Gastroenterology 138 (7), 2499-2508, 2010 | 81 | 2010 |
| Disruption of the growth hormone—signal transducer and activator of transcription 5—insulinlike growth factor 1 axis severely aggravates liver fibrosis in a mouse model of … L Blaas, JW Kornfeld, D Schramek, M Musteanu, G Zollner, J Gumhold, ... Hepatology 51 (4), 1319-1326, 2010 | 68 | 2010 |
| Bacterial artificial chromosomes improve recombinant protein production in mammalian cells L Blaas, M Musteanu, R Eferl, A Bauer, E Casanova Bmc Biotechnology 9, 1-5, 2009 | 45 | 2009 |
| Whole exome sequencing of rapid autopsy tumors and xenograft models reveals possible driver mutations underlying tumor progression T Xie, M Musteanu, PP Lopez-Casas, DJ Shields, P Olson, PA Rejto, ... PloS one 10 (11), e0142631, 2015 | 35 | 2015 |
| Myeloid STAT3 promotes formation of colitis-associated colorectal cancer in mice P Pathria, D Gotthardt, M Prchal-Murphy, EM Putz, M Holcmann, ... Oncoimmunology 4 (4), e998529, 2015 | 34 | 2015 |
| STAT3β controls inflammatory responses and early tumor onset in skin and colon experimental cancer models F Marino, V Orecchia, G Regis, M Musteanu, B Tassone, C Jon, M Forni, ... American journal of cancer research 4 (5), 484, 2014 | 29 | 2014 |
| Rapid adaptation to CDK2 inhibition exposes intrinsic cell-cycle plasticity M Arora, J Moser, TE Hoffman, LP Watts, M Min, M Musteanu, Y Rong, ... Cell 186 (12), 2628-2643. e21, 2023 | 23 | 2023 |
| RAF1 kinase activity is dispensable for KRAS/p53 mutant lung tumor progression M Sanclemente, P Nieto, S Garcia-Alonso, F Fernández-García, ... Cancer cell 39 (3), 294-296, 2021 | 23 | 2021 |
| Metabolomic evaluation of Mitomycin C and rapamycin in a personalized treatment of pancreatic cancer A Navarrete, EG Armitage, M Musteanu, A García, A Mastrangelo, R Bujak, ... Pharmacology research & perspectives 2 (6), e00067, 2014 | 23 | 2014 |
| A mouse model to identify cooperating signaling pathways in cancer M Musteanu, L Blaas, R Zenz, J Svinka, T Hoffmann, B Grabner, ... Nature methods 9 (9), 897-900, 2012 | 23 | 2012 |
| Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas M Salmón, R Álvarez-Díaz, C Fustero-Torre, O Brehey, CG Lechuga, ... The Journal of Clinical Investigation 133 (7), 2023 | 19 | 2023 |
| Structure of the RAF1-HSP90-CDC37 complex reveals the basis of RAF1 regulation S García-Alonso, P Mesa, L de la Puente Ovejero, G Aizpurua, ... Molecular cell 82 (18), 3438-3452. e8, 2022 | 19 | 2022 |
| ERK Inhibitor LY3214996-Based Treatment Strategies for RAS-Driven Lung Cancer J Köhler, Y Zhao, J Li, PC Gokhale, HL Tiv, AR Knott, MK Wilkens, ... Molecular cancer therapeutics 20 (4), 641-654, 2021 | 18 | 2021 |
| Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas L Esteban-Burgos, H Wang, P Nieto, J Zheng, C Blanco-Aparicio, ... Proceedings of the National Academy of Sciences 117 (39), 24415-24426, 2020 | 17 | 2020 |
